Tag: Leukemia and Lymphoma

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry

Background Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. When used in real-world settings, tisagenlecleucel has shown similar efficacy and improved safety compared with previous clinical trials. However, long-term data on… Continue reading Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry

Gene modification could improve cancer treatment’s success rate

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells fight cancer more effectively. These findings could improve immunotherapy for patients with aggressive cancers such as leukemia.

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Abstract Background Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity. Methods In… Continue reading Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

Background Natural Killer (NK) cells have intrinsic anticancer activity that can be redirected toward acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) engineering. Here, we study the functional consequences of CAR binding affinity and targeted epitope on CAR-NK cell activation, cytolytic synapse formation, and antitumor activity. Methods We characterized NK-92 and primary NK cell… Continue reading Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway

Background Clofarabine (Clo) is a Food and Drug Administration (FDA)-approved drug for the treatment of acute lymphoblastic leukemia; however, its effects on solid tumors remain largely unknown. Methods In vitro and in vivo experiments have demonstrated the cytotoxic effects of Clo on melanoma and lung cancer. The molecular mechanisms of Clo-induced tumor cell death were… Continue reading Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Abstract Background Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity. Methods In… Continue reading Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia

Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown that PPCL patients receiving a combination of novel agents, but not eligible for transplantation, may have a median survival up to 2 years, extended to 3… Continue reading European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1>=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC… Continue reading Determinants of 5-year survival in patients with advanced NSCLC with PD-L1>=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry